You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

You’ve been redirected to the new Cancer Care Ontario website. You can also visit the archived website, which is no longer being maintained.

Drugs

The drug library provides access to information on over 100 cancer drugs available for use in Canada.

Find more safety information in the supplementary patient handout How to Safely Take Your Oral Anti-Cancer Medication.

Displaying Drugs List

171 Items
Other Name(s): Tecentriq™
Sep 2019
Other Name(s): Bavencio(TM)
Funding:
New Drug Funding Program
  • Avelumab - Metastatic Merkel Cell Carcinoma
May 2019
Other Name(s): Inlyta®
Funding:
Exceptional Access Program
  • aXitinib - For the treatment of metastatic renal cell carcinoma of clear cell histology (second-line), according to clinical criteria
Jun 2019
Other Name(s): Vidaza® (Celgene)
Funding:
New Drug Funding Program
  • Azacitidine - Acute Myeloid Leukemia (AML)
  • Azacitidine - Intermediate-2 and high-risk myelodysplastic syndrome (MDS)
Nov 2017
Other Name(s): Treanda® (Lundbeck Canada Inc.)
Funding:
New Drug Funding Program
  • Bendamustine - First Line - Chronic Lymphocytic Leukemia
  • Bendamustine - Relapsed_Refractory - Indolent Non-Hodgkin's Lymphoma and Mantle Cell Lymphoma
  • Bendamustine - First Line - Indolent Non-Hodgkin's Lymphoma and Mantle Cell Lymphoma
Apr 2017
Other Name(s): Avastin®; Mvasi™
Funding:
New Drug Funding Program
  • Bevacizumab - Metastatic (Stage IVB), Persistent, or Recurrent Carcinoma of the Cervix
  • Bevacizumab in combination with paclitaxel and carboplatin - Front-line Treatment Ovarian Fallopian Tube and Primary Peritoneal Cancer
  • Bevacizumab - First Line - Metastatic Colorectal Small Bowel or Appendiceal Cancer
  • Bevacizumab for Platinum-Resistant Recurrent Ovarian Fallopian Tube or Primary Peritoneal Cancer
  • Bevacizumab - First Line - Metastatic Colorectal Small Bowel or Appendiceal Cancer
  • Bevacizumab - Metastatic (Stage IVB) Persistent or Recurrent Carcinoma of the Cervix
  • Bevacizumab (Biosimilar) - First Line - Metastatic Colorectal, Small Bowel, or Appendiceal Cancer
  • Bevacizumab (Biosimilar) - Metastatic (Stage IVB), Persistent, or Recurrent Carcinoma of the Cervix
  • Bevacizumab (Biosimilar) with Paclitaxel and Carboplatin - Front-line Treatment (Previously Untreated) Ovarian, Fallopian Tube, and Primary Peritoneal Cancer
Sep 2019
Other Name(s): Casodex® (multiple brands available)
Funding:
ODB - General Benefit
  • bicalutamide
Sep 2019
Sep 2019
Other Name(s): Blincyto
Funding:
New Drug Funding Program
  • Blinatumomab - Relapsed or Refractory Acute Lymphoblastic Leukemia
  • Blinatumomab – Relapsed or Refractory Pediatric Acute Lymphoblastic Leukemia
Sep 2019
Other Name(s): Velcade®
Funding:
New Drug Funding Program
  • Bortezomib - Previously Untreated - Multiple Myeloma
  • Bortezomib - Previously Untreated - Multiple Myeloma Pre-Stem Cell Transplant
  • Bortezomib - Relapsed or Refractory Multiple Myeloma
Jul 2019
Other Name(s): Bosulif®
Funding:
Exceptional Access Program
  • bosutinib - For the treatment of patients with chronic, accelerated or blast phase Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia (CML), according to specific criteria.
Jun 2019
Other Name(s): Adcetris®
Funding:
New Drug Funding Program
  • Brentuximab - Hodgkin's Lymphoma
  • Brentuximab - Systemic Anaplastic Large Cell Lymphoma
Sep 2019